Gubbiotti Marilena, Giannantoni Antonella, Cantaluppi Simona, Coluccia Anna Chiara, Ghezzi Fabio, Serati Maurizio
Department of Surgical and Biomedical Sciences, Uro- Oncology Section, University of Perugia, S. Maria della Misericordia Hospital, 06132, Perugia, Italy.
Istituto Serafico di Assisi, Centro di Ricerca "InVita", 06081, Assisi, Perugia, Italy.
BMC Urol. 2019 Jan 21;19(1):7. doi: 10.1186/s12894-019-0438-8.
Overactive bladder (OAB) can frequently exert a negative effect on female sexual function. Mirabegron, a β3 receptor agonist, improves OAB symptoms, but there are very few information about its role on female sexual dysfunction (FSD). Aim of the study was to assess the impact of Mirabegron on FSD in women affected by OAB.
Fifty sexually active women suffering from idiopathic OAB were included in the study. Patients were assessed by means of a urogynecologic physical examination and were asked to complete the 3-day voiding diary, the International Consultation on Incontinence Questionnaire- Short Form (ICIQ-SF), the Female Sexual Function Index (FSFI) questionnaire and VAS, before and 12 weeks after treatment with Mirabegron. In addition, at the same time points, patients underwent uroflowmetry with the measurement of post- void residual volume (PVR).
At baseline all patients were affected by OAB symptoms, with 49/50 patients (98%) presenting with FSD. At 12- weeks follow- up, OAB symptoms improved significantly in all patients, with 59.5% of subjects achieving a complete urinary continence. FSFI Total Score significantly improved in 42/50 patients (84%) from 18.9 ± 4.3 to 21.8 ± 4.5 (p < 0.0001). Sixteen cases (32%) presented with no FSD. Also mean ± SD scores of ICIQ-SF and VAS significantly improved (from 17.1 ± 5 to 7.9 ± 4.8 and from 3.9 ± 1.2 to 6.9 ± 1.2 respectively, p < 0.000).
Mirabegron not only is able to control urinary symptoms in women with OAB, but also induces a significant improvement in their sexual life.
膀胱过度活动症（OAB）常对女性性功能产生负面影响。米拉贝隆是一种β3受体激动剂，可改善OAB症状，但关于其对女性性功能障碍（FSD）作用的信息非常少。本研究的目的是评估米拉贝隆对患有OAB的女性FSD的影响。
50名患有特发性OAB的性活跃女性被纳入研究。患者接受了泌尿妇科体格检查，并被要求在米拉贝隆治疗前和治疗12周后完成3天排尿日记、国际尿失禁咨询问卷简表（ICIQ-SF）、女性性功能指数（FSFI）问卷和视觉模拟评分（VAS）。此外，在相同时间点，患者接受尿流率测定并测量残余尿量（PVR）。
基线时所有患者均有OAB症状，49/50例患者（98%）存在FSD。在12周随访时，所有患者的OAB症状均显著改善，59.5%的受试者实现了完全尿失禁。42/50例患者（84%）FSFI总分显著改善，从18.9±4.3提高到21.8±4.5（p<0.0001）。16例（32%）患者不再有FSD。ICIQ-SF和VAS的平均±标准差评分也显著改善（分别从17.1±5降至7.9±4.8和从3.9±1.2升至6.9±1.2，p<0.000）。
米拉贝隆不仅能够控制患有OAB女性的尿路症状，还能显著改善她们的性生活。
